Of the estimated 9.6 million people who developed tuberculosis (TB) in 2014, more than half (58%) were in the South-East Asia and Western Pacific Regions, with India, Indonesia, and China alone accounting for 43% of the world’s total TB cases.
Tuberculosis in Asia: A Region Under Threat
Multidrug-resistant TB (MDR-TB), deadly and far more expensive to treat, is on the rise, with nearly 170,000 estimated new cases in the region in 2014. Eight of the world’s 22 highest TB burden countries are located in the Asia-Pacific region. In South East Asia as in most of the world, TB incidence rates are broadly associated with poverty and limited public health infrastructure. Yet in other parts of Asia, such as China, Japan and Korea, the growing elderly population is also expected to make a significant contribution to TB incidence rates over the coming years. A particular concern for this region is its vast and mobile population, which may facilitate TB transmission and complicate diagnosis and treatment. TB is a threat that the Asia- Pacific region cannot afford to ignore.
Asia’s Urgent Need for TB Vaccines
New vaccines are at the center of future TB elimination efforts. A vaccine that prevents adolescents and adults from developing and transmitting the disease would be a highly cost-effective tool in mitigating this epidemic and preventing the spread of both drug-resistant and drug-sensitive TB.
Hope: The Film
“Hope: Developing Safe and Effective Vaccines to Fight TB” highlights China’s desire and innovative leadership in solving the global problem of TB. The film includes Chinese researchers who are leading the way in developing new vaccines to prevent tuberculosis. Featuring patients, doctors and top TB vaccine researchers, Hope illuminates China’s unique role in ending the global tuberculosis epidemic.
Aeras Asia: Regional Focus, Global Network
With our language, cultural and political expertise, Aeras Asia helps key regional stakeholders understand the landscape of TB. We connect policy makers, advocates, research organizations, governments, donors, academic institutions, industry, healthcare workers, and others throughout the region. Taking a direct role in epidemiology and clinical research projects, Aeras is advancing TB science, building capacity, strengthening partnerships and advancing a diverse portfolio of TB vaccine candidates through the R&D pipeline.
Key Activities in Asia
Aeras Asia takes an active role in TB research around the region. Some of our most recent efforts include:
- Prospective cohort study of TB recurrence in 70 districts throughout Vietnam, in partnership with Australia’s Woolcock Institute of Medical Research
- Developing new mucosal TB vaccines in collaboration with Japan’s National Institute of Biomedical Innovation and Create Vaccine Co., Ltd.
- Conducting TB prevalence surveys at two sites in China, in conjunction with China CDC and Fudan University
- Comprehensive TB vaccine development, from discovery, to preclinical and clinical research
Building Upon Progress
The Aeras Asia office, located in Beijing, China, is geographically positioned to help coordinate and strengthen regional TB efforts, fill critical gaps and improve R&D efficiency. Using diverse outlets such as print, video and social media channels, Aeras Asia promotes the urgent need for TB vaccines and advocates for increased political will to support regional efforts. We also assist stakeholders with meeting international R&D expectations and regulatory processes. Committed, experienced and engaged, Aeras Asia is a key regional leader across the spectrum of TB vaccines. Aeras is dedicated to ensuring that effective TB vaccines are available to those who need them most.
Protect Us - Chinese Healthcare Workers on the Front Lines of TB
The real-life stories of China’s top TB doctors, nurses and healthcare workers acquiring TB during work and suffering from the disease. Their experiences express the urgent need for a new, effective TB vaccine.
Contact Aeras Asia
Suite 26, 14th Floor, Tower A
Pacific Century Place Workers Stadium Road 2A
Chao Yang District, Beijing
100027, P.R. China
P: +86 10 6587 6980
F: +86 10 6539 1060